Objective To investigate if the mean central retinal thickness (CRT) amplitude, measured
between visits, is consistently decreased when switching from discontinuous to continuous …

Objective: To evaluate, in the setting of persistent diabetic macular edema, the impact that
continuous fluocinolone acetonide delivery has on treatment burden, visual acuity, central …

BACKGROUND AND OBJECTIVE: Assess fluocinolone acetonide implant (FAc) effects on
diabetic macular edema (DME) retinal thickness fluctuations. PATIENTS AND METHODS: A …

Objectives The area-under-the-curve (AUC) measures the average drug effect over time. We
investigated the impact of baseline clinical and optical coherence tomography (OCT) factors …

Objectives To evaluate central foveal thickness (CFT) variability and accompanying changes
in visual acuity (VA) 12 months before and after treatment with the 190 mcg fluocinolone …

Purpose The aim of this study was to evaluate subfoveal choroidal thickness (SFCT) as a
marker of outcome in real-world treatment of diabetic macular edema (DME) and to correlate …

Purpose: To report functional and morphologic outcomes, based on diabetic macular edema
(DME) chronicity and baseline best-corrected visual acuity (BCVA), from a subanalysis of the …

Objectives: To compare retinal thickness before and after treatment with the fluocinolone
acetonide (FAc) 190 µg intravitreal implant in people with diabetic macular edema (DME) …

AIM To report foveal thickness reduction in eyes with resolution of macular edema and
recovery of a foveal depression after one-year of anti-vascular endothelial growth factor (anti …

Purpose To evaluate retinal thickness fluctuations in patients with diabetic macular oedema
(DMO) treated with anti-vascular endothelial growth factor (anti-VEGF) injections. Methods …